IRIS
VIOLA, Anna
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 584
EU - Europa 575
AS - Asia 98
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.260
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 583
IE - Irlanda 245
SE - Svezia 184
IT - Italia 96
CN - Cina 71
SG - Singapore 16
PL - Polonia 13
FI - Finlandia 9
DE - Germania 8
IN - India 8
BE - Belgio 7
FR - Francia 7
AT - Austria 3
BR - Brasile 2
HK - Hong Kong 2
CA - Canada 1
EU - Europa 1
JP - Giappone 1
NL - Olanda 1
RO - Romania 1
UA - Ucraina 1
Totale 1.260
Salva come PNG Salva come JPEG
Città #
Dublin 243
Chandler 178
Nyköping 97
Ashburn 66
Princeton 37
Medford 33
Des Moines 24
Messina 18
Ann Arbor 13
Singapore 11
Seattle 10
Beijing 9
Jinan 9
Brussels 7
Dearborn 7
Pozzuolo Martesana 6
Rome 6
Wilmington 6
Hebei 5
Jacksonville 5
Nanjing 5
Cagliari 4
Haikou 4
Hangzhou 4
Pune 4
Shenyang 4
Tianjin 4
Bremen 3
Fuzhou 3
Lappeenranta 3
Mineo 3
Ningbo 3
Trecastagni 3
Vienna 3
Zhengzhou 3
Boardman 2
Cambridge 2
Carini 2
Changsha 2
Enna 2
Guangzhou 2
Hong Kong 2
Hyderabad 2
Jiaxing 2
Lanzhou 2
New York 2
Reggio Calabria 2
Reggio Nell'emilia 2
Squillace 2
Trezzo Sull'adda 2
Amsterdam 1
Bitonto 1
Bucharest 1
Fairfield 1
Frankfurt am Main 1
Gurgaon 1
Helsinki 1
Kunming 1
Nanchang 1
Nuremberg 1
Nürnberg 1
Ottawa 1
Padova 1
Prineville 1
Redwood City 1
San Mateo 1
Springfield 1
Taizhou 1
Tappahannock 1
Viersen 1
Vittoria 1
Totale 894
Salva come PNG Salva come JPEG
Nome #
Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study 73
Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab 57
Inflammatory Bowel Disease in the Elderly – Knowledge Gaps and Potential Directions in Research 56
Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study 56
Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD “AGED study” 55
Diagnostic accuracy of faecal calprotectin in a symptom-based algorithm for early diagnosis of inflammatory bowel disease adjusting for differential verification bias using a Bayesian approach 50
Direct oral anticoagulants increase the risk of anaemia and hospitalization in IBD patients with active intestinal disease 45
One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy 45
Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study 44
Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study 41
null 40
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis 40
Management of patients with inflammatory bowel disease and outcomes during the first wave of the Covid-19 pandemic 40
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar 39
Tissue levels of Tumour Necrosis Factor-alpha as molecular biomarker of inflammation and prediction of sustained treatment response in patients with Ulcerative Colitis. 39
Effectiveness of Ustekinumab on Crohn‘s Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD) 38
IL PAZIENTE ANZIANO CON MALATTIA INFIAMMATORIA CRONICA INTESTINALE: OSSERVAZIONI IN UN GRUPPO DI PAZIENTI AMBULATORIALI 34
null 33
Incident Colorectal Cancer in Inflammatory Bowel Disease 33
Stevens-Johnson syndrome on treatment with sulfasalazine for Crohn’s disease: Need for a multidisciplinary approach 32
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches 31
Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results from the SoCOVID-19 Survey 30
Effectiveness and Safety Profiles of Biological Therapies in Inflammatory Bowel Disease: Real Life Data from an Active Pharmacovigilance Project 28
Ménétrier's disease in a patient with refractory ulcerative colitis: a clinical challenge and review of the literature 28
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 27
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: The IG-IBD LIVE study 27
null 26
Letter: the clinical course of Crohn's disease—the Sicilian experience 25
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study 22
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD) 21
SPOSAB ABP 501 - A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501 20
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study 19
Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseases 19
Portal hypertensive enteropathy: multimodality assessment through computed tomography and magnetic resonance enterography 18
DWI ratios: New indexes for Crohn's disease activity at magnetic resonance enterography? 17
Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease 16
Comparison of two strategies for the management of postoperative recurrence in Crohn's disease patients with one clinical risk factor: A multicentre IG-IBD study 13
Prevalence, Pathogenesis and Management of Anemia in Inflammatory Bowel Disease: An IG-IBD Multicenter, Prospective, and Observational Study 13
Predictors of Covid-19 vaccination acceptance in IBD patients: a prospective study 12
Efficacy and Safety of Biological Therapies and JAK Inhibitors in Older Patients with Inflammatory Bowel Disease 11
null 10
Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy 8
Objective comparison of vedolizumab and ustekinumab effectiveness in Crohn's disease patients failure to TNF-alpha inhibitors 8
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 7
DWI ratios at MR-Enterography: a new way for inflammation degree assessment in Crohn's disease patients? 7
Quality of Life (QoL) in Patients with Chronic Inflammatory Bowel Diseases: How Much Better with Biological Drugs? 6
Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19 5
Ulcerative Colitis in Adulthood and in Older Patients: Same Disease, Same Outcome, Same Risks? 5
Low Adherence is Associated with Chronic Active Disease in Ulcerative Colitis: A Retrospective Study from a Single Referral Center 5
Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease 4
Standard Therapeutic Approach and New Therapies 3
Mitigating the Risk of Tofacitinib-induced Adverse Events in the Elderly Population with Ulcerative Colitis 2
Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study 2
Corticosteroid use in patients with inflammatory bowel diseases: A real-life sub-analysis of the Italian DICE study 2
Psychological impairment in inflammatory bowel diseases: the key role of coping and defense mechanisms 1
Totale 1.388
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.322
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.322
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202046 5 1 0 0 3 8 4 3 0 8 7 7
2020/2021152 15 12 32 4 15 4 18 5 5 19 16 7
2021/2022287 5 31 3 2 8 4 14 10 11 74 21 104
2022/2023620 39 65 30 60 29 46 15 28 277 11 14 6
2023/2024260 20 29 37 56 14 24 7 15 0 33 8 17
2024/20252 2 0 0 0 0 0 0 0 0 0 0 0
Totale 1.388